Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen IncfiledCriticalAmgen Inc
Publication of AR114079A1publicationCriticalpatent/AR114079A1/en
En este documento se proporcionan proteínas de unión a antígeno PD-1 y ácidos nucleicos relacionados, vectores, células huésped, kits y composiciones farmacéuticas. También se proporcionan métodos para fabricar proteínas de unión al antígeno PD-1 y métodos para tratar a un sujeto.Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits, and pharmaceutical compositions. Methods for making PD-1 antigen binding proteins and methods for treating a subject are also provided.
ARP190100060A2018-01-122019-01-11
ANTI-PD-1 ANTIBODIES AND TREATMENT METHODS
AR114079A1
(en)
a composition comprising a human tigit binding antigen binding domain, nucleic acid and expression vector composition, host cell, and methods for preparing an anti-tigit antibody and for treating cancer.
antibody, methods for reducing and increasing the binding affinity of a human cd3 binding antibody, for treating and diagnosing a disease, for producing an antibody, and for detecting the presence of cd3 antigen, nucleic acid construct, expression vector, host cell, composition, and kit?
isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder
antibody, chimeric antigen receptor, nucleic acid, recombinant cell, process for producing an antibody or chimeric antigen receptor, composition, and method for detecting a cll-1 expressing cell, for diagnosing a disease, for inhibiting cell division and for cancer treatment.